CSF3 and non-small cell lung carcinoma: The purpose of this study is to determine whether it is feasible to administer high-dose epirubicin (135 mg m−2) combined with a fixed dose of cisplatin every 2 weeks with G-CSF support in patients with metastatic non-small-cell lung cancer (NSCLC).